Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670 | 1.00 | — | — | |
| SCHEMBL9397770 | 0.96 | — | — | |
| SCHEMBL28871555 | 0.93 | — | — | |
| SCHEMBL5264159 | 0.81 | — | — | |
| Methylamine SCHEMBL18979545 | 0.81 | — | — | |
| SCHEMBL8751772 | 0.80 | — | — | |
| SCHEMBL2185750 | 0.72 | — | — | |
| SCHEMBL2153342 | 0.72 | — | — | |
| SCHEMBL15767062 | 0.72 | — | — | |
| SCHEMBL5931931 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024022465-A1 | HUMAN AMYLIN POLYPEPTIDE DERIVATIVE AND USE THEREOF | 杭州九源基因工程有限公司 | 2024-02-01 | — | — | WO | disclosed |
| EP-4238979-A1 | BETA-STRAND TYPE CROSSLINKED PEPTIDE | Xeno-Interface Inc. (JP) | 2023-09-06 | — | — | EP | disclosed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-20230174576-A1 | BETA-STRAND BRIDGE PEPTIDE | KYOTO UNIVERSITY (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| CN-109970720-A | A kind of Aurora A protein inhibitor and preparation method thereof and medicinal usage | 深圳先进技术研究院 | 2019-07-05 | — | — | CN | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| EP-2776394-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-12-26 | — | — | EP | disclosed |
| EP-0672679-B1 | PHOSPHOLIPASE C INHIBITING PEPTIDE | KYOWA HAKKO KOGYO KK (JP) | 1998-01-28 | — | — | EP | disclosed |
| EP-0421682-B1 | Novel peptides, intermediates therefor, process for preparing the same, and antiallergic agents, vasodilators and immunoregulators | HITACHI CHEMICAL CO LTD (JP) | 1997-03-26 | — | — | EP | disclosed |
| EP-0672679-A1 | PHOSPHOLIPASE C INHIBITING PEPTIDE | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1995-09-20 | — | — | EP | disclosed |
| US-5223487-A | Tri-, tetra-, penta- and hexapeptatides of Asp, Gly, Lys, Ser, Ala and salts | HITACHI CHEMICAL CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5095139-A | Fungicides | CIBA-GEIGY CORPORATION (US) | 1992-03-10 | — | — | US | disclosed |
| EP-0421682-A1 | Novel peptides, intermediates therefor, process for preparing the same, and antiallergic agents, vasodilators and immunoregulators | HITACHI CHEMICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-H810-H | MORPHINE AGONIST | Wilkinson, Samuel (GB) | 1990-08-07 | — | — | US | disclosed |
| EP-0122818-B1 | LIQUID-PHASE SYNTHESIS OF HPGRF (SOMATOCRININ) AND INTERMEDIATE PEPTIDES | SANOFI S.A. (FR) | 1987-10-07 | — | — | EP | disclosed |
| EP-0057419-B1 | NEW PEPTIDE, PROCESS FOR PREPARATION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-27 | — | — | EP | disclosed |
| US-4115646-A | Process for preparing 7-aminocephalosporanic acid derivatives | BEECHAM GROUP LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174576-A1 | BETA-STRAND BRIDGE PEPTIDE | IAPP, SPPL2B, VIP | TDP1 2335/4885TSHR 2483/4885ALDH1A1 4642/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | TDP1 409/4885TSHR 4274/4885ALDH1A1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.